7 / 23
Page 51
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
D
ose estimates for radiopharmaceuticals may be established based on data from preclinical (i.e. animal species) or clinical
studies (involving human patients or volunteers). This session will describe current approaches in both areas, and show
examples. Traditional mathematical model-based anatomical models have now been replaced with more realistic standardized
anatomical models based on patient image data and have been incorporated into the software code OLINDA/EXM 2.0. The
code employs these anthropomorphic models, the new International Commission on Radiological Protection (ICRP) human
alimentary tract (HAT) model and updated (ICRP 103) tissue weighting factors for calculation of effective dose. Adjustments to
traditional dose calculations based on patient specific measurements are routinely needed, especially in therapy calculations,
for marrow activity (based on measured blood parameters or image data), organ mass (based on volumes measured by
ultrasound or computed tomography (CT), and other variables. Man interesting radiopharmaceutical therapy agents are currently
in use, for thyroid disorders, neuroendocrine tumours, and treatment of bone metastases. Clinical experience, success rates,
and management of normal tissue toxicity with many nuclear medicine therapy agents will be reviewed. The need for patient
individualized approaches to therapy will be emphasized. A discussion of relevant release criteria for therapy patients will be
included.
michael.g.stabin@vanderbilt.eduNuclear medicine internal dosimetry:
measurements, models, and methods
Michael G Stabin
Vanderbilt University, USA
J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-003